News | Radiation Therapy | September 09, 2019

Accuray to Display Motion Synchronization Cancer Treatment Technologies at ASTRO 2019

Synchrony motion tracking for Radixact System, CyberKnife VOLO Optimizer among radiation therapy treatment system highlights

Accuray to Display Motion Synchronization Cancer Treatment Technologies at ASTRO 2019

September 9, 2019 — Accuray announced that it will showcase its motion-synchronization cancer treatment technologies at the upcoming 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, Sept. 15 - 18 in Chicago. The company will provide multiple opportunities for attendees to explore its new innovations in patient-first cancer treatments, including booth presentations and demonstrations at its Innovation Pavilion and presentations at the Accuray Symposium.

Synchrony Motion Tracking and Correction Technology for the Radixact System to be Unveiled

Accuray has brought its Synchrony motion synchronization technology from the CyberKnife System to the Radixact System. During the meeting, attendees will have the chance to learn how Synchrony for Radixact synchronizes the treatment delivery beam with the movement of the tumor, accurately delivering high doses of radiation directly to the tumor and minimizing dose to healthy tissue, all while the patient breathes naturally. 

Faster Radiation Treatments with the CyberKnife System

Meeting attendees can also hear more about the CyberKnife VOLO Optimizer, a next-generation optimizer that enables physicians to significantly improve operational efficiency by reducing both the time to create high quality treatment plans and the time it takes to deliver patient treatments. Clinicians now have an option for delivering the same highly precise radiosurgery and stereotactic body radiation therapy (SBRT) treatments of the CyberKnife System, more quickly and for a wider range of patient cases.

Accuray Symposium: Clinicians to Share Treatment Perspectives

At Accuray's Symposium event on, ASTRO meeting attendees will hear how dynamic tracking and motion synchronization has translated into improved patient outcomes. The symposium panelists will discuss their perspectives and share best practices on how they have used Accuray's motion synchronization technologies.

Symposium panelists will include:

  • Symposium Chairman and Introduction: Iris C. Gibbs, M.D., FACR, FASTRO, Stanford University Medical Center, Stanford, Calif.;
  • Clinical Value of Motion Synchronization for Prostate SBRT: Ronald C. Chen, M.D. MPH, University of North Carolina, Chapel Hill;
  • Clinical Value of Motion Synchronization for Lung SBRT: Jonathan W. Lischalk, M.D., Medstar Georgetown University Hospital, Washington, D.C.; and
  • First Site Experience on Real-time Motion Synchronization on the Radixact System: X. Allen Li, Ph.D., DABMP, FAAPM, Medical College of Wisconsin.

Accuray will also feature ongoing interactive discussions with industry experts in its AERO Academy. 

For more information: www.accuray.com

Related Content

News | Radiation Therapy | May 06, 2021
May 6, 2021 — Individuals living with severe...
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
#prostatecancer During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer in Sweden than in previous years.

Getty Images

News | Prostate Cancer | April 30, 2021
April 30, 2021 — During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate canc
A phase 1 clinical trial led by investigators at the University of Chicago Medicine testing the effects of stereotactic body radiotherapy for treating multiple metastases has determined that treatments used for single tumors can also be safely used for treating patients with multiple metastases.

Image courtesy of Accuray

News | Stereotactic Body Radiation Therapy (SBRT) | April 23, 2021
April 23, 2021 — A phase 1 clinical trial led by investigators at the...
A Norwegian study for the first time reveals benefit of the #PARP inhibitor #Olaparib in patients with early #breastcancer not harboring germline mutations

Getty Images

News | Radiation Therapy | April 22, 2021
April 22, 2021 — Targeted therapy in early stages of breas...
Varian announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI) based diagnostic platform to aid in the fight against cancer. Varian and Google Cloud AI embarked on a deployment journey, using Neural Architecture Search (NAS) technology via Google Cloud AI Platform, to create AI models for organ segmentation — a crucial and labor-intensive step in radiation oncology that can be a bottleneck in the cancer treatment clinical workflow.
News | Artificial Intelligence | April 08, 2021
April 8, 2021 — Varian announced it is collaborating with Google...
Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

News | Artificial Intelligence | April 07, 2021
April 7, 2021 — Vysioneer, a leader in a...
The National Comprehensive Cancer Network® (NCCN®) and the American Cancer Society (ACS) are teaming up with leading health organizations across the country to endorse the safe resumption of cancer screening and treatment during the ongoing COVID-19 pandemic.
News | Radiation Therapy | March 31, 2021
March 31, 2021 — Doctors who oversee cancer clinics say that new patients are arriving for treatment with more advanc